ReviewCurrent oncology (Toronto, Ont.)2026

Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option?

Paolo Maione et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.